The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

På svenska

Author

  • Matthieu F Bastide
  • Wassilios G Meissner
  • Barbara Picconi
  • Stefania Fasano
  • Pierre-Olivier Fernagut
  • Michael Feyder
  • Veronica Francardo
  • Cristina Alcacer
  • Yunmin Ding
  • Riccardo Brambilla
  • Gilberto Fisone
  • A Jon Stoessl
  • Mathieu Bourdenx
  • Michel Engeln
  • Sylvia Navailles
  • Philippe De Deurwaerdère
  • Wai Kin D Ko
  • Nicola Simola
  • Micaela Morelli
  • Laurent Groc
  • Maria-Cruz Rodriguez
  • Eugenia V Gurevich
  • Maryka Quik
  • Michele Morari
  • Manuela Mellone
  • Fabrizio Gardoni
  • Elisabetta Tronci
  • Dominique Guehl
  • François Tison
  • Alan R Crossman
  • Un Jung Kang
  • Kathy Steece-Collier
  • Susan Fox
  • Manolo Carta
  • Angela Cenci Nilsson
  • Erwan Bézard
Show all

Summary, in English

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.

Publishing year

2015

Language

English

Pages

96-168

Publication/Series

Progress in Neurobiology

Volume

132

Issue

Jul 21

Document type

Journal article review

Publisher

Elsevier

Topic

  • Neurology

Status

Published

Research group

  • Basal Ganglia Pathophysiology

ISBN/ISSN/Other

  • ISSN: 1873-5118